Physician profile
James E Flanagan
NPI 1124476379
$5,857.07
in general payments reported to CMS, 2019-2025
28 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $112 · 2021: $857 · 2022: $819 · 2023: $480 · 2024: $886 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692 · Travel and Lodging: $818 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,691.63 |
| Travel and Lodging | $817.60 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,586.24 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $683.03 | 2019-2025 | Tezspire, Fasenra |
| Inari Medical, INC. | $449.20 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $361.18 | 2020-2025 | Brinsupri, Arikayce |
| Fisher & Paykel Healthcare INC | $344.05 | 2023 | Fisher & Paykel Healthcare |
| Ethicon INC. | $316.45 | 2019-2023 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.05 | 2020-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $276.54 | 2019-2021 | |
| Glaxosmithkline, LLC. | $275.81 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $194.94 | 2023-2025 | Inspire |
| United Therapeutics Corporation | $165.97 | 2019-2022 | |
| Abbott Laboratories | $156.29 | 2025 | 2nd Gen Centrimag Primary Console |
| Stryker Corporation | $147.35 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $125.09 | 2025 | |
| Pulmonx Corporation | $121.43 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $85.55 | 2019 | |
| Genzyme Corporation | $47.41 | 2022-2025 | |
| Haemonetics Corporation | $37.88 | 2022-2025 | Teg6s Hemostasis System |
| Becton, Dickinson and Company | $32.37 | 2025 | Hemosphere |
| Jazz Pharmaceuticals INC. | $30.15 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $24.14 | 2025 | Dupixent |
| Electromed, INC. | $21.07 | 2021 | |
| Verona Pharma, INC. | $20.23 | 2025 | Ohtuvayre |
| Amgen INC. | $19.35 | 2022 | |
| Edwards Lifesciences Corporation | $15.49 | 2021 | |
| Baxter Healthcare | $14.66 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $13.92 | 2021 | |
| Circassia INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.